I failed 3lines of TKIs,I can try thisagent nextAfter 3months, I have3% BCR-ABL,I have this TKIresponseModerateto highemetogenicrisk TKIsTKIs aremajorsubstratesfor this liverenzymePatients havepresence of thisBCR-ABLproteinindicative ofCML The numberof distinctclinicalphases inCMLDrug classthatrevolutionizedCMLtreatmentThe scoringsystem usedin chronicphaseWhen togive H2RAswithdasatinibResponsewhen BCR-ABL1 (IS)is <0.01%Number ofblastspresent inacceleratedphaseTranslocationbetweenthese twochromosomesoccur in CMLThelandmarkfor thefirst TKIPercentageof blastspresent inthe blastphaseNon-pharmacologicaltreatment forCML60-70% ofpatients withCML presentwith thissymptomI have theT315I mutationbut also haveelevated lipaseI avoid thisdrug classwith bosutinib,nilotinib anddasatinibToo many ofthese bloodcells areabnormal inCMLThe current5-yearoverallsurvival rateof CMLTherecommendedcriteria usedfor acceleratedphaseTreatmentfor blastphaseCMLI want toavoid thisTKI if I donot wantdiarrheaThis TKI hasthe mostmetabolicsyndromeI failed 3lines of TKIs,I can try thisagent nextAfter 3months, I have3% BCR-ABL,I have this TKIresponseModerateto highemetogenicrisk TKIsTKIs aremajorsubstratesfor this liverenzymePatients havepresence of thisBCR-ABLproteinindicative ofCML The numberof distinctclinicalphases inCMLDrug classthatrevolutionizedCMLtreatmentThe scoringsystem usedin chronicphaseWhen togive H2RAswithdasatinibResponsewhen BCR-ABL1 (IS)is <0.01%Number ofblastspresent inacceleratedphaseTranslocationbetweenthese twochromosomesoccur in CMLThelandmarkfor thefirst TKIPercentageof blastspresent inthe blastphaseNon-pharmacologicaltreatment forCML60-70% ofpatients withCML presentwith thissymptomI have theT315I mutationbut also haveelevated lipaseI avoid thisdrug classwith bosutinib,nilotinib anddasatinibToo many ofthese bloodcells areabnormal inCMLThe current5-yearoverallsurvival rateof CMLTherecommendedcriteria usedfor acceleratedphaseTreatmentfor blastphaseCMLI want toavoid thisTKI if I donot wantdiarrheaThis TKI hasthe mostmetabolicsyndrome

Chronic Myeloid Leukemia BINGO - Call List

(Print) Use this randomly generated list as your call list when playing the game. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
O
2
I
3
G
4
I
5
B
6
O
7
N
8
B
9
G
10
B
11
O
12
G
13
G
14
B
15
O
16
G
17
N
18
I
19
N
20
I
21
N
22
I
23
B
24
O
  1. O-I failed 3 lines of TKIs, I can try this agent next
  2. I-After 3 months, I have 3% BCR-ABL, I have this TKI response
  3. G-Moderate to high emetogenic risk TKIs
  4. I-TKIs are major substrates for this liver enzyme
  5. B-Patients have presence of this BCR-ABL protein indicative of CML
  6. O-The number of distinct clinical phases in CML
  7. N-Drug class that revolutionized CML treatment
  8. B-The scoring system used in chronic phase
  9. G-When to give H2RAs with dasatinib
  10. B-Response when BCR-ABL1 (IS) is <0.01%
  11. O-Number of blasts present in accelerated phase
  12. G-Translocation between these two chromosomes occur in CML
  13. G-The landmark for the first TKI
  14. B-Percentage of blasts present in the blast phase
  15. O-Non-pharmacological treatment for CML
  16. G-60-70% of patients with CML present with this symptom
  17. N-I have the T315I mutation but also have elevated lipase
  18. I-I avoid this drug class with bosutinib, nilotinib and dasatinib
  19. N-Too many of these blood cells are abnormal in CML
  20. I-The current 5-year overall survival rate of CML
  21. N-The recommended criteria used for accelerated phase
  22. I-Treatment for blast phase CML
  23. B-I want to avoid this TKI if I do not want diarrhea
  24. O-This TKI has the most metabolic syndrome